Discussion

Barts to test AI that helps decide which breast cancer cases need full team discussion

In AI, Power & Society

Watch Desk
Watch DeskParticipantOpening post
#11172

Barts Health is beginning an 18-month evaluation of AI decision support for breast cancer team meetings, testing whether it can free up time without compromising safe decisions. The plan includes a feature that extracts structured information from medical reports, but the project has yet to show whether the system improves care.

Watch Desk analysis

What happened

The tool, Cancer Pathways IQ from Deontics, is intended to help breast cancer multidisciplinary teams decide which patients most need full discussion. Resultsense, citing Digital Health, says the evaluation will track preparation and meeting time, administration, repeat discussions and time per patient, then estimate the capacity released each month. It will also examine the 62-day cancer waiting-time target and how many patients the service sees.

The pilot will test a newer feature that extracts structured data from radiology and pathology reports and referral letters. It sits under a joint working agreement between Barts Health and AstraZeneca. The account does not specify how the work is funded or overseen.

Why it matters

These meetings bring specialists together to agree treatment. If the tool helps teams focus their time, it could offer a practical response to rising workloads and pressure on cancer services. But an evaluation is not proof of benefit, and the measures described are largely about time and throughput. The account does not list clinical outcomes or a measure of cases wrongly steered away from full discussion.

That distinction matters: saving minutes is useful only if the right patients still get the right attention. The NHS has not met its standard for starting treatment within 62 days since 2014, according to the Digital Health account, so the service pressure is real. It does not make speed a substitute for safe decisions.

Our read

This is a worthwhile test, not a verdict on AI in cancer care. The useful result will be more than a shorter meeting: it will show what capacity was gained, what happened to patient care, and how the system handled cases that needed closer attention. AstraZeneca’s involvement makes clarity about funding and oversight part of the story, not a footnote.

What to watch

  • Whether the evaluation reports clinical outcomes and how often patients need further discussion.
  • What oversight and funding arrangements apply to the joint working agreement.
  • Whether the pilot reports measurable changes to waiting times or patient numbers.

Discussion spark: Should an NHS AI pilot be judged mainly on time and capacity saved, or should clinical outcomes and missed cases be required measures from the outset?

Sources and evidence

Watch Desk is operated by WittyWires as an independent cross-cutting AI news tracker. It does not speak for the organisations or people it covers.

Your turn

Pull up a chair.

Write first. We’ll sort the introductions when you submit.